NASDAQ:DARE - Dare Bioscience Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.8450 +0.02 (+2.42 %)
(As of 02/22/2019 04:00 PM ET)
Previous Close$0.83
Today's Range$0.82 - $0.86
52-Week Range$0.60 - $1.70
Volume80,764 shs
Average Volume38,223 shs
Market Capitalization$9.65 million
P/E Ratio-0.68
Dividend YieldN/A
Beta2.23
Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, focuses on developing and marketing women's reproductive health products in the United States. The company intends to develop therapies in the areas of contraception, vaginal health, sexual health, and fertility. Its product candidates include Ovaprene, a non-hormonal monthly contraceptive; and SST-6007, a topical sildenafil cream for female sexual arousal disorder. The company has license and collaboration agreement with Strategic Science and Technologies-D, LLC and Strategic Science Technologies, LLC to develop and commercialize indications for women related to female sexual dysfunction and/or female reproductive health. The company was incorporated in 2005 and is headquartered in San Diego, California.

Receive DARE News and Ratings via Email

Sign-up to receive the latest news and ratings for DARE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DARE
CUSIPN/A
Phone858-926-7655

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Cash Flow$0.6079 per share
Book Value$2.20 per share

Profitability

Net Income$-11,500,000.00

Miscellaneous

Employees5
Market Cap$9.65 million
Next Earnings Date4/1/2019 (Estimated)
OptionableNot Optionable

Dare Bioscience (NASDAQ:DARE) Frequently Asked Questions

What is Dare Bioscience's stock symbol?

Dare Bioscience trades on the NASDAQ under the ticker symbol "DARE."

How were Dare Bioscience's earnings last quarter?

Dare Bioscience Inc (NASDAQ:DARE) announced its earnings results on Monday, August, 13th. The biotechnology company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.23) by $0.09. View Dare Bioscience's Earnings History.

When is Dare Bioscience's next earnings date?

Dare Bioscience is scheduled to release their next quarterly earnings announcement on Monday, April 1st 2019. View Earnings Estimates for Dare Bioscience.

What price target have analysts set for DARE?

2 brokerages have issued 12 month price targets for Dare Bioscience's stock. Their forecasts range from $3.00 to $6.00. On average, they expect Dare Bioscience's share price to reach $4.50 in the next twelve months. This suggests a possible upside of 432.5% from the stock's current price. View Analyst Price Targets for Dare Bioscience.

What is the consensus analysts' recommendation for Dare Bioscience?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dare Bioscience in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Dare Bioscience.

Has Dare Bioscience been receiving favorable news coverage?

News stories about DARE stock have been trending positive recently, according to InfoTrie. The research group rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Dare Bioscience earned a news sentiment score of 2.3 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 3.0 out of 10, indicating that recent media coverage is unlikely to have an effect on the company's share price in the near future.

Who are some of Dare Bioscience's key competitors?

What other stocks do shareholders of Dare Bioscience own?

Who are Dare Bioscience's key executives?

Dare Bioscience's management team includes the folowing people:
  • Ms. Sabrina Martucci Johnson, Pres, CEO, Sec. & Director (Age 52)
  • Ms. Lisa Walters-Hoffert, Chief Financial Officer (Age 60)
  • Mr. Mark Walters, VP of Operations (Age 64)
  • Dr. David Friend, Chief Scientific Officer
  • Mr. John Fair, Chief Bus. Officer

Who are Dare Bioscience's major shareholders?

Dare Bioscience's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Geode Capital Management LLC (0.92%). View Institutional Ownership Trends for Dare Bioscience.

Which major investors are buying Dare Bioscience stock?

DARE stock was acquired by a variety of institutional investors in the last quarter, including Geode Capital Management LLC. View Insider Buying and Selling for Dare Bioscience.

How do I buy shares of Dare Bioscience?

Shares of DARE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Dare Bioscience's stock price today?

One share of DARE stock can currently be purchased for approximately $0.8450.

How big of a company is Dare Bioscience?

Dare Bioscience has a market capitalization of $9.65 million. The biotechnology company earns $-11,500,000.00 in net income (profit) each year or ($1.24) on an earnings per share basis. Dare Bioscience employs 5 workers across the globe.

What is Dare Bioscience's official website?

The official website for Dare Bioscience is http://www.darebioscience.com.

How can I contact Dare Bioscience?

Dare Bioscience's mailing address is 3655 NOBEL DRIVE SUITE 260, SAN DIEGO CA, 92122. The biotechnology company can be reached via phone at 858-926-7655 or via email at [email protected]


MarketBeat Community Rating for Dare Bioscience (NASDAQ DARE)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  235 (Vote Outperform)
Underperform Votes:  167 (Vote Underperform)
Total Votes:  402
MarketBeat's community ratings are surveys of what our community members think about Dare Bioscience and other stocks. Vote "Outperform" if you believe DARE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DARE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel